Lilly's GLP-1 franchise continues to beat expectations, driving another guidance raise and a record stock price despite US pricing pressure.

The accelerated nod gives INOVIO a US marketing authorization and a potential revenue path for its lead candidate.

Big pharma's quarterly results show pricing negotiations have yet to dent top-line growth across the sector.

The data intensify competition among next-generation multi-agonist obesity drugs from Lilly and rivals.

The readout shapes the regulatory path for Vertex's pain program, a key non-CF growth bet.

An oral GLP-1 success adds a pill-based contender to the crowded obesity and diabetes market.

The extension delays a potential approval decision in a rare-disease franchise for Agios.

The label expansion broadens Sun Pharma's immunology drug into a new inflammatory indication.

The miss clouds expansion of Iovance's cell therapy beyond its approved indications.

Another late-stage Alzheimer's failure underscores the difficulty of the CNS drug pipeline.

The weekly roundup captures a mix of approvals, restructuring and dealmaking across biopharma.

The injectable-device maker's results indicate demand beyond obesity drugs supports its outlook.

The company is targeting the post-obesity-drug maintenance market with an endoscopic approach.

Local pricing competition in Korea signals broader pressure on branded GLP-1 economics.

India's ceiling-price revision lowers costs for older oncology drugs while sparing patented products.

EU-US friction over drug pricing and tariffs escalates into talk of trade retaliation.

Election outcomes could reshape the political footing of recent US drug-pricing agreements.

US pressure on German reference pricing adds to transatlantic tension over pharma costs.